hepat
c
viru
hcv
smallenvelop
rna
viru
belong
flavivirida
famili
sinc
first
identifi
hcv
estim
infect
million
peopl
worldwid
mostli
chronic
hepat
c
viru
uniform
natur
histori
liver
cirrhosi
develop
hepatocellular
carcinoma
current
therapi
hcv
infect
consist
combin
pegyl
interferon
ribavirin
hand
hcvrelat
liver
diseas
also
lead
indic
liver
transplant
howev
posttranspl
hcv
reinfect
graft
report
univers
furthermor
graft
hcv
reinfect
often
result
acceler
progress
liver
failur
addit
treatment
recurr
hcv
infect
liver
transplant
often
compromis
enhanc
advers
effect
limit
efficaci
interferonbas
therapi
taken
togeth
poor
outcom
hcv
reinfect
regardless
graft
recipi
pose
major
issu
hepatologist
transplant
surgeon
aim
paper
review
sever
specif
aspect
regard
hcv
reinfect
transplant
risk
factor
current
therapeut
hcv
differ
stage
liver
transplant
cellular
function
hcv
protein
molecular
mechan
hcv
entri
hope
paper
inspir
new
strategi
novel
inhibitor
recurr
hcv
infect
liver
transplant
greatli
improv
overal
outcom
hepat
c
viru
hcv
member
flavivirida
famili
viru
seven
major
genotyp
genotyp
identifi
distinct
region
distribut
pattern
hcv
major
caus
chronic
hepat
worldwid
endstag
liver
diseas
caus
hcv
increasingli
becom
lead
indic
liver
transplant
lt
well
known
hcv
reinfect
follow
lt
examin
hcv
rna
detect
use
polymeras
chain
reaction
occur
almost
univers
natur
histori
hcv
reinfect
substanti
chang
lt
acceler
rate
cirrhosi
recurr
year
point
hcv
reinfect
liver
graft
time
reperfus
intraop
viru
sourc
attribut
blood
high
probabl
viral
load
return
pretranspl
valu
within
day
transplant
may
influenc
usag
corticosteroid
acut
hepat
occur
month
transplant
character
acut
lobular
hepat
earli
reinfect
stage
graft
injuri
occur
week
chronic
hepat
establish
month
transplant
stage
chronic
hepat
character
decreas
viral
load
pattern
immunemedi
injuri
variant
form
posttranspl
hcv
infect
cholestat
hepat
c
occur
patient
frequent
associ
high
viral
load
immunosuppress
usual
occur
within
month
transplant
progress
hepat
failur
month
form
character
high
viral
load
cellular
balloon
low
inflamm
intrahepat
immunolog
respons
featur
suggest
liver
lesion
due
direct
cytopath
injuri
caus
hcv
date
absenc
prevent
strategi
hcv
reinfect
transplant
major
challeng
hcv
recipi
undergo
lt
mention
reinfect
liver
graft
univers
character
acceler
progress
liver
diseas
furthermor
treatment
recurr
hcv
infect
lt
compromis
enhanc
advers
effect
limit
efficaci
interferonbas
therapi
addit
poor
outcom
graft
reinfect
hcv
increasingli
becom
major
problem
face
hepatologist
transplant
surgeon
thu
novel
prevent
therapeut
strategi
hcv
reinfect
urgent
need
recurr
hcv
infect
liver
allograft
univers
lt
natur
histori
variabl
estim
approxim
recipi
progress
graft
cirrhosi
within
year
transplant
overal
hcv
diseas
aggress
posttranspl
recipi
patient
whose
immun
intact
acceler
diseas
progress
multifactori
probabl
depend
number
variabl
includ
host
donor
viral
extern
factor
howev
definit
interact
factor
recurr
hcv
infect
liver
allograft
still
remain
controversi
poorli
defin
thu
identifi
recipi
risk
rapid
hcv
recurr
lt
help
especi
consid
treatment
current
avail
antivir
agent
either
prophylaxi
therapi
date
number
risk
factor
mention
regard
clinic
issu
one
studi
review
patient
underw
lt
hcv
period
suggest
advanc
donor
age
prolong
donor
hospit
increas
recipi
age
elev
recipi
meld
score
found
increas
rel
risk
hcv
recurr
moreov
earlier
studi
advoc
hcv
recurr
may
sever
older
donor
use
addit
type
donor
use
may
impact
hcv
reinfect
graft
lt
one
clinic
observ
suggest
hcv
recurr
sever
live
donor
lt
compar
cadaver
lt
howev
anoth
studi
report
differ
observ
hepat
c
recurr
rate
sever
intrahepat
patholog
graft
patient
surviv
live
donor
lt
cadaver
lt
recipi
sourc
hcv
reinfect
allograft
may
occur
time
reperfus
intraop
blood
high
probabl
origin
allograft
reinfect
inde
valuabl
identifi
risk
factor
lt
particularli
match
donor
hcv
recipi
may
decreas
incid
hcv
recurr
lt
load
hcv
infect
allograft
believ
extrem
dynam
process
hcv
viru
bind
new
allograft
time
reperfus
viral
replic
occur
within
hour
lt
impact
recipi
viral
load
hcv
recurr
follow
lt
still
uncertain
clear
understand
hcv
kinet
lt
contribut
develop
strategi
prevent
hcv
infect
allograft
earlier
studi
analyz
hcv
kinet
immedi
lt
found
sharp
decreas
hcv
viral
load
anhepat
phase
immedi
graft
reperfus
decreas
presum
attribut
massiv
bind
hcv
hepatocyt
word
reinfect
immedi
reperfus
power
et
al
also
report
hcv
rna
level
drop
averag
halflif
hour
anhepat
phase
author
also
mention
viral
load
continu
drop
hour
implant
began
rise
soon
hour
anhepat
phase
moreov
viral
load
reach
plateau
rise
suggest
nonhepat
sourc
suppli
virion
balanc
intrins
clearanc
estim
nonhepat
sourc
respons
total
viral
product
remain
occur
liver
similar
studi
point
viral
load
serum
return
pretranspl
level
within
hour
procedur
within
week
transplant
viral
load
would
approxim
log
higher
pretranspl
level
howev
studi
investig
impact
pretranspl
viral
load
likelihood
hcv
recurr
produc
controversi
result
sever
report
indic
pretranspl
viral
load
correl
either
likelihood
time
hcv
recurr
follow
lt
contrast
one
studi
includ
hcvinfect
recipi
demonstr
transplant
hcv
viral
load
greater
million
viral
equivalentsml
associ
decreas
graft
patient
surviv
given
hypothesi
pretranspl
treatment
hcv
reduc
prevent
hcv
posttranspl
recurr
advoc
patient
hcv
infect
transplant
list
consid
therapi
goal
obtain
sustain
virolog
respons
svr
prior
lt
influenc
hcv
genotyp
hcv
recurr
lt
assess
result
still
controversi
studi
demonstr
sever
recurr
level
viral
replic
hcv
hepat
lt
higher
patient
genotyp
hcv
infect
genotyp
anoth
studi
gayowski
et
al
report
result
rate
recurr
hcv
hepat
time
recurr
sever
recurr
respons
ifn
therapi
differ
among
genotyp
suggest
hcv
genotyp
may
signific
factor
influenc
postlt
hcv
hepat
recent
genet
variat
region
gene
chromosom
code
demonstr
strongli
associ
svr
patient
genotyp
chronic
hcv
infect
treat
pegifn
plu
rbv
nontranspl
set
polymorph
also
associ
spontan
hcv
clearanc
one
cohort
studi
clinic
development
immunolog
includ
consecut
hcv
patient
undergo
lt
aim
determin
preval
impact
clinic
outcom
donor
recipi
genotyp
among
liver
transplant
recipi
author
suggest
recipi
tt
genotyp
associ
sever
histolog
recurr
hcv
lt
cc
donor
graft
might
preferenti
alloc
recipi
hcv
infect
reactiv
herp
group
virus
may
also
one
factor
associ
hcv
recurr
lt
cytomegaloviru
cmv
human
herp
herp
virus
commonli
reactiv
transplant
propos
immunomodulatori
effect
transplant
recipi
may
play
role
promot
hcv
replic
recent
retrospect
studi
first
lt
recipi
donor
recipi
cmv
seroposit
transplant
hcv
perform
evalu
associ
cmv
infect
diseas
recurr
hepat
c
lt
found
cmv
infect
associ
increas
risk
fibrosi
stage
inflamm
grade
howev
effect
posttranspl
hcv
recurr
still
remain
question
data
show
shortterm
cmv
viremia
enhanc
replic
hcv
lt
immunosuppress
earli
data
examin
pathogenesi
graft
injuri
liver
transplant
recipi
hcv
infect
first
report
methylprednisolon
treatment
acut
reject
led
increas
serum
hcv
rna
sinc
aggrav
cours
hcv
reinfect
lt
increas
resist
antivir
therapi
attribut
applic
specif
immunosuppress
medic
herein
variou
immunosuppress
strategi
evalu
influenc
hcv
recurr
glucocorticoid
glucocorticoid
often
given
induct
protocol
lt
low
dose
combin
immunosuppress
use
mainten
immunosuppress
oper
case
acut
reject
recipi
receiv
puls
methylprednisolon
revers
reject
convinc
data
bolu
dose
glucocorticoid
given
reject
treatment
neg
impact
hcv
recurr
estim
cumul
exposur
corticosteroid
associ
increas
mortal
higher
level
hcv
viremia
sever
histolog
recurr
one
recent
studi
demonstr
glucocorticosteroid
specif
increas
hcv
entri
upregul
cell
entri
factor
occludin
scaveng
receptor
class
b
type
data
suggest
potenti
effect
highdos
glucocorticosteroid
hcv
infect
vivo
may
due
increas
hcv
dissemin
previou
studi
indic
specif
cell
respons
hcv
import
viral
clearanc
acut
hcv
infect
liver
transplant
moreov
plasmacytoid
dendrit
cell
capabl
produc
larg
amount
ifn
hcv
infect
specif
cell
respons
experiment
data
shown
prednisolon
suppress
function
plasmacytoid
dendrit
cell
promot
apoptosi
thu
transplant
set
consensu
steroid
avoid
slow
taper
dose
associ
reduc
hcv
recurr
wherea
bolus
treat
acut
reject
increas
viral
load
calcineurin
inhibitor
cni
cyclosporin
lipophil
cyclic
peptid
amino
acid
tacrolimu
macrolid
antibiot
drug
bind
high
affin
famili
cytoplasm
protein
also
call
immunophilin
present
varieti
immun
cell
immunophilindepend
signal
transduct
via
calcineurin
repres
key
event
activ
cell
prolifer
regul
express
gene
encod
cyclosporin
cya
bind
cyclophilin
tacrolimu
tac
bind
fk
bind
protein
fkbp
bind
block
phosphatas
activ
calcineurin
subsequ
inhibit
cell
prolifer
blockag
product
intriguingli
addit
promot
role
calcineurin
signal
immunophilin
catalyst
protein
fold
contribut
invas
abil
sever
coronavirus
hcv
well
establish
cyclophilin
import
role
viral
replic
de
novo
viru
product
recent
data
suggest
hcv
replic
depend
interact
cyclophilin
b
nonstructur
protein
hcv
rna
polymeras
stimul
rna
bind
activ
therebi
promot
de
novo
synthesi
posit
neg
strand
rna
given
fact
immunophilin
work
support
role
viral
infect
ration
find
cya
capabl
antihcv
activ
mediat
specif
blockad
cyclophilin
rna
cya
interact
cyclophilin
cyclophilin
b
conceiv
cya
affect
multipl
step
life
cycl
hcv
howev
controversi
antihcv
effect
cyclosporin
vivo
contrast
tac
antihcv
activ
mmf
mpa
mycophenol
mofetil
mmf
belong
class
antimetabolit
immunosuppress
agent
mycophenol
acid
mpa
activ
metabolit
mmf
select
noncompetit
inhibitor
inosin
monophosph
dehydrogenas
impdh
addit
potent
immunosuppress
capac
vitro
assay
indic
mpa
antivir
effect
hcv
hcv
cell
cultur
model
mpa
could
induc
express
import
antivir
interferonstimul
gene
includ
interferon
regulatori
factor
irf
irf
interferoninduc
transmembran
protein
among
protein
data
show
directli
involv
antihcv
activ
mpa
moreov
mpa
could
effect
synergi
ifnon
hcv
replic
hcv
experi
addit
combin
ifn
mpa
augment
transcript
multipl
interferonstimul
gene
molecular
basi
mpa
work
synergi
ifn
proper
prospect
clinic
studi
warrant
confirm
synergist
effect
hcv
vivo
hand
although
safeti
efficaci
mmf
immunosuppress
medic
hcv
patient
undergo
lt
demonstr
exact
effect
hcv
recurr
clearli
studi
rapamycin
low
nephrotox
potenti
anticanc
properti
rapamycin
increasingli
use
transplant
context
well
known
rapamycin
engag
cytosol
protein
form
complex
complex
inhibit
mtor
pathway
directli
bind
mtor
complex
result
blockag
cell
cycl
progress
phase
therebi
caus
inhibit
cell
prolifer
intriguingli
rapamycin
induc
autophagi
inhibit
mtor
autophagi
process
catabol
organel
intracellular
compon
balanc
cellular
metabol
promot
cell
surviv
stress
condit
fact
autophagi
also
import
event
regul
cellular
respons
viral
infect
noteworthi
hcv
infect
induc
autophagi
hepatocyt
via
unfold
protein
respons
autophagi
induc
hcv
incomplet
block
matur
autophagosom
autolysosom
autophagosom
degrad
instead
support
viral
replic
recent
studi
demonstr
could
directli
interact
host
protein
induc
autophagi
addit
hcvinduc
autophagi
may
promot
infect
reduc
innat
immun
base
find
conceiv
rapamycin
could
affect
hcv
recurr
antivir
interferon
therapi
howev
clinic
evid
need
make
sure
vivo
effect
hcv
reinfect
graft
almost
univers
among
recipi
activ
infect
time
transplant
acceler
progress
fibrosi
note
recipi
recurr
hcv
transplant
least
patient
eventu
develop
liver
cirrhosi
within
year
liver
cirrhosi
establish
first
episod
decompens
may
occur
high
patient
within
year
apart
rapid
progress
fibrosi
recipi
recurr
hepat
c
may
also
develop
sever
fibros
cholestat
hepat
character
jaundic
rapidli
organ
transplant
absenc
biliari
obstruct
caus
high
risk
graft
failur
reason
hcvrelat
recipi
show
wors
posttranspl
outcom
compar
hcvneg
recipi
previou
studi
retrospect
analyz
patient
liver
transplant
confirm
hcv
infect
significantli
impair
patient
graft
surviv
lt
focus
strategi
recurr
hcv
infect
lt
three
approach
identifi
accord
time
treatment
pretransplant
antivir
therapi
posttransplant
prevent
preemptiv
treatment
treatment
establish
reinfect
noteworthi
none
patient
achiev
svr
lt
develop
graft
reinfect
studi
addit
rel
poor
efficaci
safeti
pegyl
ifn
anoth
concern
patient
decompens
cirrhosi
carrion
et
al
report
patient
suffer
discontinu
decompens
death
therapi
although
incid
decompens
death
similar
comparison
control
group
treat
patient
suffer
significantli
higher
rate
bacteri
infect
control
group
childpugh
bc
independ
factor
associ
bacteri
infect
data
suggest
patient
decompens
cirrhosi
close
monitor
pegyl
ifn
therapi
follow
expert
consider
experi
direct
act
antivir
daa
includ
proteas
polymeras
nonstructur
protein
inhibitor
newli
develop
agent
hcv
treatment
current
data
hcv
treatment
use
daa
limit
patient
cirrhosi
phase
iii
trial
telaprevir
boceprevir
patient
advanc
fibrosi
compens
cirrhosi
includ
although
result
phase
iii
trial
telaprevir
boceprevir
tripl
therapi
show
higher
svr
rate
compar
pegyl
ifnrbv
therapi
advanc
fibrosi
cirrhot
patient
sever
advanc
event
rate
also
increas
patient
receiv
tripl
therapi
data
compassion
use
proteas
inhibitor
viral
c
cirrhosi
cupic
cohort
also
demonstr
increas
seriou
advers
event
rate
discontinu
rate
cirrhot
nonrespond
compar
phase
iii
trial
anoth
studi
cirrhot
patient
await
lt
demonstr
patient
achiev
undetect
hcv
rna
week
daa
tripl
therapi
howev
patient
suffer
earli
discontinu
patient
decompens
therapi
result
suggest
tripl
therapi
must
administ
cautious
intens
safeti
monitor
cirrhot
patient
acceler
clinic
cours
recurr
hepat
c
lt
strategi
prevent
reinfect
graft
need
antihepat
b
immunoglobulin
approv
success
prevent
hbv
recurr
lt
use
antibodi
therapi
hcvinfect
recipi
howev
recent
studi
use
hepat
c
immunoglobulin
monoclon
antibodi
show
transient
decreas
liver
hcv
rna
level
liver
transplant
recipi
preemptiv
earli
posttranspl
antivir
therapi
aim
prevent
rapid
develop
chronic
hepat
evid
recurr
hcv
infect
usual
initi
within
one
month
lt
compar
immunocompet
subject
antivir
therapi
respons
decreas
period
high
level
immunosuppress
pilot
studi
mazzaferro
collect
hcvrna
cirrhot
patient
start
ifn
plu
rbv
combin
therapi
within
week
lt
sustain
virolog
respons
svr
achiev
patient
none
patient
develop
graft
reject
normal
histolog
also
note
patient
svr
median
followup
month
howev
higher
graft
reject
note
anoth
studi
use
ifn
rbv
combin
therapi
month
moreov
four
studi
use
differ
regiment
two
ifn
monotherapi
two
pegylatedifn
monotherapi
show
poor
effect
less
svr
higher
rate
treatment
discontinu
graft
reject
therefor
prospect
largesc
studi
still
need
investig
appropri
regimen
preemptiv
treatment
owe
rel
poor
efficaci
high
advers
effect
expert
delay
antivir
therapi
till
histolog
evid
recurr
hcv
infect
establish
lt
howev
patient
diagnos
fibros
cholestat
hepat
antivir
therapi
must
given
earli
possibl
lt
poor
shortterm
prognosi
rapid
fibrosi
progress
initi
convent
ifnbas
therapi
use
treat
recurr
hcv
infect
lt
systemat
review
consist
studi
total
patient
demonstr
mean
svr
rate
convent
ifnbas
therapi
compar
convent
ifnbas
therapi
pegyl
ifnbas
therapi
show
signific
improv
svr
rate
three
recent
systemat
review
demonstr
svr
rate
genotyp
genotyp
subject
use
pegyl
ifnbas
therapi
recurr
hepat
c
lt
result
also
found
histolog
improv
regardless
necroinflamm
fibrosi
factor
predict
better
svr
also
nontranspl
patient
genotyp
low
pretreat
hcv
rna
rapid
virolog
respons
adher
therapi
identifi
posit
predictor
associ
respons
recipientdonor
liver
genotyp
also
report
recent
charlton
fibros
cholestat
hepat
anoth
poor
predictor
almost
incur
ifn
treatment
fibros
cholestat
hepat
develop
safeti
toler
therapi
also
among
major
concern
lt
recipi
hcv
recurr
dose
reduct
discontinu
acut
reject
note
patient
treat
convent
ifnbas
therapi
patient
treat
pegyl
ifn
therapi
better
svr
rate
note
comparison
ifnbas
group
meanwhil
reject
rate
also
found
elev
mean
rate
highest
addit
dose
reduct
note
patient
treatment
discontinu
found
around
patient
treatment
genotyp
hcv
infect
first
gener
daa
telaprevir
boceprevir
recent
use
enhanc
efficaci
standard
regiment
pegyl
ifn
plu
rbv
although
daa
significantli
increas
svr
rate
patient
relaps
nonrespond
evid
still
limit
efficaci
recurr
hcv
infect
lt
addit
limit
safeti
toler
one
critic
limit
potenti
interact
cni
one
recent
studi
healthi
volunt
show
boceprevir
increas
area
curv
csa
tac
respect
anoth
studi
report
concomit
administr
immunosuppress
therapi
telaprevir
healthi
volunt
increas
csa
tac
exposur
approxim
respect
sever
team
commun
preliminari
result
daa
use
lt
summar
coilli
et
al
overal
week
tripl
therapi
complet
earli
virolog
respons
evr
obtain
patient
treat
boceprevir
patient
treat
telaprevir
notabl
csa
dose
reduc
boceprevir
fourfold
telaprevir
tac
dose
reduc
fivefold
boceprevir
telaprevir
conclud
daa
could
complet
chang
prognosi
patient
sever
hcv
recurr
offer
new
perspect
treatment
hcv
recurr
liver
transplant
patient
current
therapi
hcv
infect
consist
combin
pegyl
interferon
ifn
ribavirin
rbv
limit
resist
advers
effect
high
cost
absenc
prevent
regiment
major
limit
patient
undergo
lt
hcvrelat
liver
failur
moreov
acceler
progress
liver
cirrhosi
graft
reinfect
limit
efficaci
ifnbas
therapi
recurr
hcv
two
major
clinic
issu
lead
poor
posttranspl
outcom
hcv
recipi
thu
novel
prevent
therapeut
antivir
urgent
need
viral
entri
requir
initi
spread
mainten
infect
hcv
entri
multistep
process
orchestr
number
viral
host
cell
factor
factor
includ
viral
envelop
glycoprotein
scaveng
receptor
tight
junction
protein
occlud
clear
understand
detail
mechan
hcv
entri
may
shed
light
way
prevent
liver
graft
hcv
recurr
cell
humor
respons
often
thought
play
key
role
control
hcv
infect
clinic
set
patient
spontan
resolv
acut
hcv
infect
tend
earli
induct
neutral
antibodi
respons
contrast
chronic
infect
patient
delay
initi
neutral
antibodi
respons
moreov
varieti
strategi
viru
evolv
escap
antibodiesmedi
neutral
includ
acceler
evolut
divers
hcv
overal
capac
hcv
mutat
continu
allow
high
plastic
abil
viru
adapt
variabl
environment
condit
escap
host
immun
respons
lead
hcv
persisten
hcv
entri
hepatocyt
requir
interact
viral
envelop
glycoprotein
cell
membran
contain
put
fusion
domain
littl
known
role
hcv
entri
sever
domain
defin
bind
cd
scaveng
receptor
class
b
type
srbi
two
import
host
factor
describ
next
paragraph
interact
glycoprotein
help
hcv
evad
host
immun
respons
enter
hepatocyt
exampl
hypervari
region
first
amino
acid
play
import
role
viral
fit
demonstr
involv
srbimedi
hcv
entri
therefor
suggest
target
neutral
antibodi
high
variabl
result
poor
crossneutr
potenc
antibodi
across
differ
hcv
isol
well
known
host
humor
respons
thought
play
critic
role
control
hcv
infect
sever
studi
report
broadli
neutral
antibodi
might
direct
conserv
conform
epitop
within
mostli
inhibit
interact
current
new
conform
conserv
epitop
identifi
ntermin
part
conserv
natur
epitop
hold
great
promis
develop
potent
inhibitor
hcv
entri
sever
cell
surfac
molecul
target
cell
identifi
interact
hcv
includ
ldl
receptor
highli
sulfat
heparan
sulfat
hs
srbi
occludin
ocln
ubiquit
express
kda
tetraspanin
demonstr
interact
solubl
truncat
form
hcv
larg
extracellular
loop
lel
seem
play
critic
role
interact
process
moreov
studi
identifi
sever
amino
acid
residu
throughout
lel
hcv
might
crucial
bind
srbi
kda
glycoprotein
larg
extracellular
loop
highli
express
liver
physiolog
srbi
bind
varieti
lipoprotein
eg
hdl
ldl
involv
bidirect
cholesterol
transport
cell
membran
lel
srbi
demonstr
interact
recent
studi
suggest
interplay
lipoprotein
srbi
hcv
envelop
glycoprotein
requir
hcv
entri
cldn
critic
compon
tight
junction
regul
paracellular
permeabl
polar
kda
fourtransmembran
protein
predominantli
express
liver
intriguingli
may
local
tight
junction
basolater
surfac
hepatocyt
recent
studi
suggest
nonjunct
may
also
involv
hcv
entri
ocln
kda
four
transmembran
protein
express
tight
junction
polar
cell
sever
studi
shown
ocln
probabl
involv
late
postbind
event
hcv
entri
hcv
circul
blood
associ
ldl
vldl
ldl
receptor
also
propos
attach
andor
entri
factor
hcv
ldlr
shown
mediat
intern
serumderiv
hcv
cell
bind
virusldl
particl
sinc
cholesterol
shown
necessari
hcv
cell
entri
ration
cholesteroluptak
receptor
might
also
role
process
recent
niemannpick
cholesterol
absorpt
receptor
cell
surfac
cholesterolsens
receptor
demonstr
new
hcv
entri
factor
use
function
rnai
kinas
screen
recent
studi
identifi
epiderm
growth
factor
receptor
egfr
ephrin
receptor
two
receptor
tyrosin
kinas
rtk
regul
number
key
cellular
function
host
factor
hcv
entri
result
show
identifi
rtk
mediat
hcv
entri
regul
coreceptor
associ
viral
glycoproteindepend
membran
fusion
impli
inhibit
rtk
function
may
constitut
new
approach
prevent
treatment
hcv
infect
process
process
tightli
orchestr
sever
viral
host
factor
brief
hcv
believ
first
interact
hs
ldlr
membran
surfac
hepatocyt
allow
concentr
virion
subsequ
interact
host
factor
srbi
ocln
ultim
lead
viral
intern
via
socal
clathrinmedi
endocytosi
fusion
viral
endosom
membran
follow
releas
viral
genom
cytosol
translat
replic
take
place
final
hcv
particl
assembl
releas
hepatocyt
recent
accumul
data
tri
unravel
potenti
molecular
mechan
hcv
entri
fluoresc
reson
energi
transfer
fret
studi
describ
critic
role
associ
coreceptor
hcv
entri
next
ratelimit
role
srbi
hcv
infect
report
vitro
studi
demonstr
increas
srbi
express
would
enhanc
entri
intern
hcv
sever
studi
investig
postbind
cellular
mechan
found
abil
hcv
penetr
hepatocyt
may
depend
clathrinmedi
endocytosi
intern
fusion
occur
viral
endosom
membran
recent
assay
show
fusion
may
low
ph
temperatur
depend
facilit
cholesterol
although
detail
molecular
mechan
hcv
entri
still
need
investig
conceiv
hcv
intern
fusion
may
offer
mani
target
develop
hcv
entri
inhibitor
interf
hcv
entri
hepatocyt
hold
great
promis
develop
novel
drug
sever
potenti
target
suggest
block
virustarget
cell
interact
attach
bind
interf
postbind
event
interf
viral
fusion
variou
modal
may
adopt
hcv
entri
inhibitor
neutral
antibodi
hcv
envelop
glycoprotein
block
antibodi
specif
host
factor
small
molecular
compound
host
factor
viral
protein
one
potenti
target
imidazolebas
compound
mimick
alpha
helix
lel
compet
hcv
bind
drug
bind
revers
manner
block
interact
effect
neither
express
interact
physiolog
partner
molecul
addit
recent
studi
demonstr
antibodi
complet
protect
human
liverupascid
mice
subsequ
challeng
hcv
consensu
strain
differ
genotyp
howev
administr
antibodi
viral
challeng
effect
antisrbi
antibodi
block
interact
srbi
hcv
anoth
interest
strategi
prevent
hcv
entri
antisrbi
antibodi
demonstr
inhibit
hcvcc
infect
vitro
moreov
small
molecul
inhibitor
srbi
recent
develop
exampl
compound
inhibit
entri
hcvpp
major
genotyp
hcvcc
infect
without
affect
viral
replic
addit
recent
studi
demonstr
human
monoclon
antibodi
target
srbi
effici
preclud
hcv
infect
viral
spread
lt
vitro
vivo
kinet
studi
suggest
small
molecul
inhibitor
target
hcv
entri
earli
postbind
stage
suggest
play
import
role
cellcel
transmiss
recent
antibodi
inhibit
hcv
infect
vitro
develop
result
shown
antibodi
effici
block
cell
entri
highli
infecti
escap
variant
hcv
resist
host
neutral
antibodi
mention
egfr
two
newli
establish
host
factor
hcv
entri
thu
respect
inhibitor
erlotinib
dasatinib
also
regard
promis
hcv
inhibitor
prevent
hcv
reinfect
lt
addit
cell
surfac
express
host
factor
hcv
intern
fusion
complex
process
also
offer
sever
target
antivir
recent
studi
demonstr
long
phosphorothio
oligonucleotid
pson
inhibit
hcv
intern
without
affect
viral
bind
replic
human
liverchimer
albupascid
mous
model
also
show
pson
block
de
novo
hcv
infect
data
shed
light
promis
pson
futur
clinic
solut
recurr
hcv
infect
liver
transplant
increasingli
becom
major
clinic
issu
hepatologist
transplant
surgeon
face
past
decad
numer
therapeut
approach
base
basic
research
clinic
evid
report
effect
strategi
still
need
effort
approv
meanwhil
mani
critic
question
remain
sever
aspect
hcv
includ
viral
infect
cycl
activ
detail
structur
composit
function
hcv
virion
host
cell
addit
current
standard
therapeut
formula
consist
pegyl
ifn
combin
ribavirin
inhibitor
ineffect
partial
effect
fact
review
paper
mani
novel
inhibitor
neutral
antibodi
target
hcv
protein
host
factor
hold
promis
effect
prevent
treat
hcv
hope
futur
strategi
improv
overal
outcom
hcv
recipi
liver
transplant
